Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SKN016
MIFTS: 64

Skin Disease

Categories: Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Skin Disease

About this section

MalaCards integrated aliases for Skin Disease:

Name: Skin Disease 38 12 15
Abnormality of the Skin 29 6
Skin Diseases, Genetic 44 73
Skin Diseases 55 44
Skin and Subcutaneous Tissue Disease 12
Dermatologic Disorders 73
Genodermatosis 12
Skin Disorder 15

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:37
ICD9CM 35 702
NCIt 50 C27554 C3371
Sources

Summaries for Skin Disease

About this section
Disease Ontology : 12 An integumentary system disease that is located in skin.

MalaCards based summary : Skin Disease, also known as abnormality of the skin, is related to bullous skin disease and vesiculobullous skin disease, and has symptoms including pruritus, dry skin and enanthema. An important gene associated with Skin Disease is FLG (Filaggrin), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and t cells, and related phenotypes are craniofacial and integument

Sources

Related Diseases for Skin Disease

About this section

Diseases related to Skin Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 475)
# Related Disease Score Top Affiliating Genes
1 bullous skin disease 33.9 COL17A1 DSG1 DSG3 DST
2 vesiculobullous skin disease 33.8 COL17A1 COL7A1 DST KRT14 LAMC2
3 neurotic excoriation 32.6 COL17A1 COL7A1 DST
4 psoriasis 32.4 CDSN FLG IL4 KRT10 KRT14 LOR
5 hidradenitis suppurativa 32.3 KRT10 KRT14 TNF
6 dermatitis 32.3 DSG1 FLG IL4 SPINK5
7 pemphigus 32.2 COL17A1 DSG1 DSG3 DST
8 dermatitis, atopic 32.1 CDSN FLG IL4 LOR SPINK5 TNF
9 tungiasis 32.1 IL4 TNF
10 bullous pemphigoid 32.0 COL17A1 DSG1 DSG3 DST LAMC2
11 epidermolysis bullosa 31.9 COL17A1 COL7A1 DST KRT14 LAMC2
12 cellulitis 31.9 COL17A1 DSG1 DSG3 DST TNF
13 erythrokeratodermia variabilis et progressiva 1 31.9 GJB3 GJB4 LOR
14 epidermolytic hyperkeratosis 31.9 FLG KRT1 KRT10 LOR
15 ichthyosis 31.9 ABCA12 FLG KRT1 KRT10 LOR SPINK5
16 autosomal recessive congenital ichthyosis 31.8 ABCA12 FLG GJB4 KRT10 LOR SPINK5
17 linear iga disease 31.8 COL17A1 DST
18 herpes gestationis 31.8 COL17A1 DST
19 ichthyosis bullosa of siemens 31.5 KRT1 KRT10
20 subcorneal pustular dermatosis 31.4 COL17A1 DSG1 DSG3 DST
21 cicatricial pemphigoid 31.4 COL17A1 DST LAMC2
22 keratosis 31.4 DSG1 FLG KRT1 KRT10
23 pemphigoid gestationis 31.4 COL17A1 DST
24 white sponge nevus 1 31.4 KRT1 KRT10 KRT14
25 contact dermatitis 31.3 FLG IL4 TNF
26 ichthyosis, cyclic, with epidermolytic hyperkeratosis 31.3 KRT1 KRT10
27 allergic contact dermatitis 31.2 FLG IL4 TNF
28 hidradenitis 30.2 KRT10 KRT14 TNF
29 palmoplantar keratosis 30.0 DSG1 GJB3 KRT1 LOR
30 striate palmoplantar keratoderma 30.0 DSG1 KRT1 KRT10 KRT14
31 pemphigus vulgaris 30.0 DSG1 DSG3 DST
32 netherton syndrome 30.0 DSG1 FLG SPINK5 TGM1
33 pemphigus foliaceus 29.8 DSG1 DSG3 DST
34 paraneoplastic pemphigus 29.8 COL17A1 DSG1 DSG3 DST
35 epidermolysis bullosa dystrophica 29.8 COL7A1 DST FLG
36 autoimmune disease 29.8 COL17A1 DSG1 IL4 TNF
37 ichthyosis, congenital, autosomal recessive 4b 29.8 ABCA12 FLG TGM1
38 ichthyosis vulgaris 29.8 FLG KRT10 LOR SPINK5 TGM1
39 vohwinkel syndrome 29.6 LOR TGM1
40 granulomatous slack skin disease 12.2
41 vascular skin disease 12.0
42 degos 'en cocarde' erythrokeratoderma 11.7
43 keratolytic winter erythema 11.6
44 incontinentia pigmenti 11.3
45 neurofibromatosis, type ii 11.1
46 epidermodysplasia verruciformis 11.1
47 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 11.1
48 ulerythema ophryogenesis 11.1
49 psoriatic arthritis 11.0
50 rosacea 11.0

Graphical network of the top 20 diseases related to Skin Disease:



Diseases related to Skin Disease
Sources

Symptoms & Phenotypes for Skin Disease

About this section

UMLS symptoms related to Skin Disease:


pruritus, dry skin, enanthema, exanthema, skin manifestations, nasal itching

MGI Mouse Phenotypes related to Skin Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.5 ABCA12 COL7A1 DSG3 IL4 KRT14 LAMC2
2 integument MP:0010771 9.4 ABCA12 COL7A1 DSG1 DSG3 GJB3 IL4
Sources

Drugs & Therapeutics for Skin Disease

About this section

Drugs for Skin Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1367)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
2 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
3
Acitretin Approved Phase 4,Phase 3,Phase 2,Not Applicable 55079-83-9 5284513 6437841
4
mometasone furoate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
6
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
7
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
8
Petrolatum Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 8009-03-8
9
Titanium dioxide Approved Phase 4,Phase 2,Not Applicable 13463-67-7
10
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
11
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 815610-63-0
12
Desonide Approved, Investigational Phase 4,Phase 3,Not Applicable 638-94-8 5311066
13
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 119141-88-7 4594 9579578
14
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
15
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
16
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
17
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
18
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
20
Amorolfine Approved, Investigational Phase 4,Phase 3 78613-35-1
21
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
22
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
23
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
24
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
25
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
26
Glycerol Approved, Investigational Phase 4,Phase 1,Not Applicable 56-81-5 753
27
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
28
Mineral oil Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 8042-47-5
29
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
30
Aminolevulinic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
31
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 69-72-7 338
32
Isotretinoin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4759-48-2 5538 5282379
33
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
34
Fexofenadine Approved, Investigational Phase 4,Phase 2 83799-24-0 3348
35
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
36
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
37
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
38
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
39
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
40
acetic acid Approved Phase 4 64-19-7 176
41
Hydroquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 123-31-9 785
42
Fluticasone Approved, Experimental Phase 4,Early Phase 1,Not Applicable 90566-53-3 62924
43
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137071-32-0 6447131 17753757
44
Azelaic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 123-99-9 2266
45
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6
46
Zinc oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 1314-13-2
47
Coal tar Approved Phase 4,Phase 3,Phase 1,Not Applicable 8007-45-2
48
Methylene blue Approved, Investigational Phase 4,Phase 3,Not Applicable 61-73-4
49
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
50
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site Unknown status NCT02400372 Phase 4
2 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
3 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
5 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
6 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
7 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
8 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
9 The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
10 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
11 Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity Unknown status NCT02602925 Phase 4
12 Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
13 A Study to Evaluate the Effectiveness of STELARA â„¢ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
14 Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
15 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
16 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
17 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
18 Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
19 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
20 Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation Unknown status NCT02904564 Phase 4
21 Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy Unknown status NCT01844141 Phase 4 70% alcohol;70% alcohol - 0.5% clorhexidine
22 Efficacy & Safety of Clindamycin and Tretinoin in Acne Unknown status NCT01111994 Phase 4 Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
23 Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
24 Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
25 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
26 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
27 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
28 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
29 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
30 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Unknown status NCT02944461 Phase 4 Dapsone 7.5 % gel
31 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
32 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4 Pregabalin;Placebo
33 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
34 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
35 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
36 Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers. Unknown status NCT01734109 Phase 4
37 Clinical Trial of Hydroquinone Versus Miconazol in Melasma Unknown status NCT01661556 Phase 4 Miconazole;Hydroquinone
38 Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care Unknown status NCT01595347 Phase 4 Hyper-oxigenated fatty acid
39 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
40 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
41 Azelaic Acid Versus Hydroquinone in Melasma Unknown status NCT00927771 Phase 4 azelaic acid gel;hydroquinone cream
42 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
43 Study on the Effects of Oxygen-ozone Therapy on Back Pain in Subjects Aged 65 or Older Unknown status NCT01709058 Phase 4 Intramuscular/paravertebral injections of Oxygen-Ozone
44 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
45 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
46 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Unknown status NCT02982148 Phase 4
47 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
48 Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Unknown status NCT02903524 Phase 4 Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;pirarubicin and cyclophosphamide
49 Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer Unknown status NCT02781259 Phase 4 Indocyanine green
50 Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer Unknown status NCT02766530 Phase 4

Search NIH Clinical Center for Skin Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Skin Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Skin Disease:
JACE�, cultured epidermis for skin replacement
Embryonic/Adult Cultured Cells Related to Skin Disease:
Cultured epidermis (JACE�) PMIDs: 23265935 17465819 11987545

Cochrane evidence based reviews: skin diseases

Sources

Genetic Tests for Skin Disease

About this section

Genetic tests related to Skin Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Skin 29
Sources

Anatomical Context for Skin Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Disease:

19
Skin

MalaCards organs/tissues related to Skin Disease:

41
Skin, T Cells, Testes, Bone, Endothelial, Neutrophil, Colon
Sources

Publications for Skin Disease

About this section

Articles related to Skin Disease:

(show top 50) (show all 1030)
# Title Authors Year
1
Simplifying Skin Disease Diagnosis with Topical Nanotechnology. ( 29772963 )
2018
2
Miscellaneous skin disease and the metabolic syndrome. ( 29241760 )
2018
3
Skin disease prevalence study in schoolchildren in rural CA'te d'Ivoire: Implications for integration of neglected skin diseases (skin NTDs). ( 29771976 )
2018
4
Molecular characterization of lumpy skin disease virus in Namibia, 2017. ( 29869033 )
2018
5
The impact of pediatric skin disease on self-esteem. ( 29872673 )
2018
6
Neuromodulation in Inflammatory Skin Disease. ( 29427206 )
2018
7
Serological and clinical evaluation of the Yugoslavian RM65 sheep pox strain vaccine use in cattle against lumpy skin disease. ( 29873893 )
2018
8
Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin disease. ( 29857917 )
2018
9
Identification and characterization of lumpy skin disease virus isolated from cattle in the Republic of North Ossetia-Alania in 2015. ( 29363284 )
2018
10
Gaps in Workplace Education For Prevention of Occupational Skin Disease. ( 29220520 )
2018
11
Epidemiology of tattoo skin disease in captive common bottlenose dolphins (Tursiops truncatus): Are males more vulnerable than females? ( 29353509 )
2018
12
Owner-reported flea treatment measures and skin disease in cats. ( 29788829 )
2018
13
Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-I_B and production of inflammatory cytokines. ( 29847604 )
2018
14
Spatial and temporal distribution of lumpy skin disease outbreaks in Uganda (2002-2016). ( 29859091 )
2018
15
Epithelial proliferation in inflammatory skin disease is regulated by tetratricopeptide repeat domain 7 (Ttc7) in fibroblasts and lymphocytes. ( 29775636 )
2018
16
Wild primates threaten efforts to wipe out skin disease. ( 29446404 )
2018
17
Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease. ( 29953999 )
2018
18
Malnutrition and skin disease in Far East prisoners-of-war in World War II. ( 29855062 )
2018
19
Characterisation of putative immunomodulatory gene knockouts of lumpy skin disease virus in cattle towards an improved vaccine. ( 29941325 )
2018
20
Phylogenetic analysis of the lumpy skin disease viruses in northwest of Iran. ( 29948777 )
2018
21
Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. ( 29858547 )
2018
22
Risk of introduction of lumpy skin disease in France by the import of vectors in animal trucks. ( 29889905 )
2018
23
Neonatal Phototherapy: A Novel Therapy to Prevent Allergic Skin Disease for At Least 5 Years. ( 29940600 )
2018
24
Skin and Diet: An Update on the Role of Dietary Change as a Treatment Strategy for Skin Disease. ( 29357214 )
2018
25
Detection of vaccine-like lumpy skin disease virus in cattle and Musca domestica L. flies in an outbreak of lumpy skin disease in Russia in 2017. ( 29932512 )
2018
26
Complete Genome Sequence of a Lumpy Skin Disease Virus Strain Isolated from the Skin of a Vaccinated Animal. ( 29853513 )
2018
27
The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. ( 29545809 )
2018
28
Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. ( 29114741 )
2018
29
Gallic acid inhibits the expression of keratin 16 and keratin 17 through Nrf2 in psoriasis-like skin disease. ( 30293051 )
2018
30
Esculetin Ameliorates Psoriasis-Like Skin Disease in Mice by Inducing CD4+Foxp3+ Regulatory T Cells. ( 30258447 )
2018
31
Fn14 deficiency ameliorates psoriasis-like skin disease in a murine model. ( 30038329 )
2018
32
The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease. ( 29619128 )
2018
33
Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis. ( 29487945 )
2018
34
Transglutaminase 1 Replacement Therapy Successfully Mitigates the ARCI Phenotype in Full-Thickness Skin Disease Equivalents. ( 30448383 )
2018
35
The emotional burden of chronic skin disease dominates physical factors among women, adversely affecting quality of life and sexual function. ( 30470317 )
2018
36
Assessing skin disease and associated health-related quality of life in a rural Lao community. ( 30509232 )
2018
37
Letter to the Editor concerning "Serological and clinical evaluation of the Yugoslavian RM65 sheep pox strain vaccine use in cattle against lumpy skin disease" by Abutarbush and Tuppurainen (Transbound Emerg Dis; 2018: DOI: 10.1111/tbed.12923). ( 30520269 )
2018
38
Spatial analysis of lumpy skin disease (LSD) in Eurasia - Predicting areas at risk for further spread within the region. ( 30520550 )
2018
39
3rd Inflammatory Skin Disease Summit-The Translational Revolution December 12 - 15, 2018 Vienna, Austria. ( 30536469 )
2018
40
Analysis and insights into recombination signals in lumpy skin disease virus recovered in the field. ( 30540759 )
2018
41
Neethling vaccine proved highly effective in controlling lumpy skin disease epidemics in the Balkans. ( 30553537 )
2018
42
Spread rate of lumpy skin disease in the Balkans, 2015-2016. ( 28239954 )
2018
43
Rasch Analysis of the Dermatology Life Quality Index Reveals Limited Application to Chinese Patients with Skin Disease. ( 28676885 )
2018
44
UK trends of allergic occupational skin disease attributed to fragrances 1996-2015. ( 29076574 )
2018
45
Stress and skin disease quality of life: the moderating role of anxiety sensitivity social concerns. ( 29078254 )
2018
46
Detection of lumpy skin disease virus in skin lesions, blood, nasal swabs and milk following preventive vaccination. ( 29086485 )
2018
47
A risk adjustment approach to estimating the burden of skin disease in the United States. ( 29110889 )
2018
48
ITK and RLK Inhibitor PRN694 Improves Skin Disease in Two Mouse Models of Psoriasis. ( 29129599 )
2018
49
Outbreak investigation and molecular diagnosis of Lumpy skin disease among livestock in Saudi Arabia 2016. ( 29150916 )
2018
50
A study of skin disease spectrum occurring in Angola phototype V-VI population in Luanda. ( 29573271 )
2018
Sources

Variations for Skin Disease

About this section

ClinVar genetic disease variations for Skin Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 COL7A1 NM_000094.3(COL7A1): c.425A> G (p.Lys142Arg) single nucleotide variant Pathogenic rs121912856 GRCh37 Chromosome 3, 48630971: 48630971
2 COL7A1 NM_000094.3(COL7A1): c.425A> G (p.Lys142Arg) single nucleotide variant Pathogenic rs121912856 GRCh38 Chromosome 3, 48593538: 48593538
3 COL7A1 NM_000094.3(COL7A1): c.2005C> T (p.Arg669Ter) single nucleotide variant Pathogenic rs780261665 GRCh37 Chromosome 3, 48627691: 48627691
4 COL7A1 NM_000094.3(COL7A1): c.2005C> T (p.Arg669Ter) single nucleotide variant Pathogenic rs780261665 GRCh38 Chromosome 3, 48590258: 48590258
5 FLG NM_002016.1(FLG): c.544A> T (p.Lys182Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 1, 152314342: 152314342
6 FLG NM_002016.1(FLG): c.544A> T (p.Lys182Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 1, 152286818: 152286818
7 KRT1 NM_006121.3(KRT1): c.744T> A (p.Asp248Glu) single nucleotide variant Uncertain significance GRCh37 Chromosome 12, 53072388: 53072388
8 KRT1 NM_006121.3(KRT1): c.744T> A (p.Asp248Glu) single nucleotide variant Uncertain significance GRCh38 Chromosome 12, 52678604: 52678604
Sources

Expression for Skin Disease

About this section
Search GEO for disease gene expression data for Skin Disease.
Sources

Pathways for Skin Disease

About this section

Pathways related to Skin Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Developmental Biology 66
Show member pathways
 12.91 CDSN DSG1 DSG3 FLG KRT1 KRT10
2
Keratinization 66
Show member pathways
 11.78 CDSN DSG1 DSG3 FLG KRT1 KRT10
3
Cytoskeleton remodeling Neurofilaments 22
Show member pathways
 11.47 DST KRT1 KRT14
4
G-protein signaling_Rap2B regulation pathway 22
10.46 COL17A1 COL7A1 IL4 LAMC2 TNF
Sources

GO Terms for Skin Disease

About this section

Cellular components related to Skin Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.91 COL17A1 DSG1 DSG3 DST GJB3 GJB4
2 extracellular matrix GO:0031012 9.8 COL17A1 COL7A1 KRT1 LAMC2
3 collagen-containing extracellular matrix GO:0062023 9.78 COL17A1 COL7A1 FLG LAMC2
4 cell-cell junction GO:0005911 9.67 CDSN COL17A1 DSG1 GJB3
5 basement membrane GO:0005604 9.46 COL17A1 COL7A1 DST LAMC2
6 desmosome GO:0030057 9.43 CDSN DSG1 DSG3
7 hemidesmosome GO:0030056 9.4 COL17A1 DST
8 intermediate filament GO:0005882 9.35 DST FLG KRT1 KRT10 KRT14
9 epidermal lamellar body GO:0097209 9.32 ABCA12 SPINK5
10 cornified envelope GO:0001533 9.23 CDSN DSG1 DSG3 FLG KRT1 KRT10
11 extracellular region GO:0005576 10.11 CDSN COL17A1 COL7A1 IL4 KRT1 KRT10

Biological processes related to Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.93 CDSN COL7A1 DSG1 DSG3 DST LAMC2
2 extracellular matrix organization GO:0030198 9.8 COL17A1 COL7A1 LAMC2 SPINK5 TNF
3 epidermis development GO:0008544 9.77 CDSN COL17A1 COL7A1 KRT14 LAMC2
4 peptide cross-linking GO:0018149 9.72 FLG KRT1 KRT10 LOR TGM1
5 keratinocyte differentiation GO:0030216 9.63 ABCA12 CDSN FLG KRT10 LOR TGM1
6 establishment of skin barrier GO:0061436 9.61 ABCA12 FLG KRT1
7 hemidesmosome assembly GO:0031581 9.56 COL17A1 DST KRT14 LAMC2
8 keratinization GO:0031424 9.56 ABCA12 DSG1 DSG3 KRT1 KRT10 KRT14
9 positive regulation of protein localization to cell surface GO:2000010 9.48 ABCA12 TNF
10 cornification GO:0070268 9.32 CDSN DSG1 DSG3 FLG KRT1 KRT10

Molecular functions related to Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.35 DST FLG KRT1 KRT10 LOR
2 structural constituent of epidermis GO:0030280 8.92 FLG KRT1 KRT10 LOR
Sources

Sources for Skin Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....